253 related articles for article (PubMed ID: 9816325)
1. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
[TBL] [Abstract][Full Text] [Related]
2. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
5. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
6. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
8. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
11. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Goldberg RM; Reid JM; Ames MM; Sloan JA; Rubin J; Erlichman C; Kuffel MJ; Fitch TR
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2363-70. PubMed ID: 9815635
[TBL] [Abstract][Full Text] [Related]
19. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
